contact us  |  privacy policy

Sunday, July 5, 2009
  • Font size
  • Bookmark
  • Save

Celebrex - Patient Info

celecoxib

Saturday, Oct. 20, 2007; 7:18 AM

Information for Patients:

CELEBREX can cause discomfort and, rarely, more serious side effects, such as gastrointestinal bleeding, which may result in hospitalization and even fatal outcomes. Although serious GI tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative signs or symptoms. Patients should be apprised of the importance of this follow-up (see WARNINGS - Gastrointestinal (GI) Effects - Risk of Gastrointestinal Ulceration, Bleeding, and Perforation).

Patients should promptly report signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, unexplained weight gain, or edema to their physicians.

Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy.

Patients should also be instructed to seek immediate emergency help in the case of an anaphylactoid reaction (see WARNINGS).

In late pregnancy CELEBREX should be avoided because it may cause premature closure of the ductus arteriosus.

Patients with familial adenomatous polyposis (FAP) should be informed that CELEBREX has not been shown to reduce colorectal, duodenal or other FAP-related cancers, or the need for endoscopic surveillance, prophylactic or other FAP-related surgery. Therefore, all patients with FAP should be instructed to continue their usual care while receiving CELEBREX.

Laboratory Tests:

Because serious GI tract ulcerations and bleeding can occur without warning symptoms, physicians should monitor for signs or symptoms of GI bleeding.

In controlled clinical trials, elevated BUN occurred more frequently in patients receiving CELEBREX compared with patients on placebo. This laboratory abnormality was also seen in patients who received comparator NSAIDs in these studies. The clinical significance of this abnormality has not been established.

  • Font size
  • Bookmark
  • Was this helpful? Yes
  • Save
TheHealthCentralNetwork  
Acid Reflux Connection Bipolar Connect My Diabetes Central High Blood Pressure Connection My Osteoarthritis Central
Allergy Network My Breast Cancer Network My Diet Exercise Incontinence Network My RA Central
Our Alzheimer's Cholesterol Network Erectile Dysfunction Connection My Migraine Connection Schizophrenia Connection
Anxiety Connection Chronic Pain Connection Herpes Connection Osteoporosis Connection Skin Cancer Connection
Asthma Central My Depression Connection My Heart Central Prostate Commons My Sleep Central